@article{a62f93f4ab184fd3bb90586f654d7659,
title = "Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review",
abstract = "The risk of herpes zoster (HZ) and HZrelated complications is increased in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) relative to the general population; therefore, HZ vaccination is recommended in these patient groups. In this literature-based review, we summarise the available evidence on the use of HZ vaccines in patients with RA and PsA, and discuss strategies for managing breakthrough infection. Currently available data show suboptimal rates of HZ vaccination among these patients and highlight a need for strategies to improve HZ vaccination programmes in clinical practice. Further clinical studies are also required to optimise the use of HZ vaccines in patients with RA and PsA, particularly with regard to determining the impact of different immunosuppressive therapy regimens on vaccine immunogenicity and, ultimately, efficacy, as well as the impact of vaccination on disease activity and safety.",
keywords = "Herpes zoster, Immunisation, Psoriatic arthritis, Rheumatoid arthritis, Vaccination",
author = "Winthrop, {Kevin L.} and Yoshiya Tanaka and Lee, {Eun Bong} and J{\"u}rgen Wollenhaupt and {Al Enizi}, Ahmad and Azevedo, {Valderilio F.} and Curtis, {Jeffrey R.}",
note = "Funding Information: Funding: this work was funded by Pfiz‑ er Inc. Medical writing support, under the guidance of the authors, was provid‑ ed by Karen Irving, PhD, CMC Con‑ nect, McCann Health Medical Commu‑ nications and Kirsteen Munn, PhD, on behalf of CMC Connect, and was fund‑ ed by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015; 163: 461-4). Pfizer employ‑ ees reviewed and provided feedback on the manuscript content for the authors{\textquoteright} consideration. The authors retained full editorial control of the content. Funding Information: this work was funded by Pfiz? er Inc. Medical writing support, under the guidance of the authors, was provid? ed by Karen Irving, PhD, CMC Con? nect, McCann Health Medical Commu? nications and Kirsteen Munn, PhD, on behalf of CMC Connect, and was fund? ed by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015; 163: 461-4). Pfizer employ? ees reviewed and provided feedback on the manuscript content for the authors? consideration. The authors retained full editorial control of the content. Publisher Copyright: {\textcopyright} Copyright Clinical and Experimental Rheumatology 2022.",
year = "2022",
month = jan,
language = "English (US)",
volume = "40",
pages = "162--172",
journal = "Clinical and experimental rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "1",
}